Global Research on Antimicrobial Resistance (GRAM)
Global Research on Antimicrobial Resistance (GRAM) is the flagship project of the Oxford GBD (Global Burden of Disease) Group, and aims to provide robust, comprehensive and timely evidence of the burden of antimicrobial resistance (AMR) globally.
There is currently very little data on the incidence, prevalence or burden of AMR in low- and middle-income countries (LMICs), which limits our understanding of the impact that AMR is having on human and animal health, and inhibits the development and targeting of appropriate interventions.
The overall aim is to strengthen the evidence base on the current global burden of AMR, and how, where and why it is changing. This will provide the essential health intelligence to help drive awareness, support better surveillance, and prompt policy action to control AMR, including facilitating antimicrobial stewardship.
University of Oxford’s Centre for Tropical Medicine and Global Health and the Institute for Health Metrics and Evaluation
Wellcome Trust and The Bill and Melinda Gates Foundation (Phase 1 only)
Phase 1: June 2016 - June 2021
Phase 2: until March 2025
Phase 1: £6.2m
Phase 2: £5.15m
Objectives
- Integrate AMR estimation by pathogen-antibacterial combination effectively and efficiently into the GBD annual enterprise and produce sustainable longitudinal estimates post 2025.
- Expand the set of combinations of pathogens and outcomes to include two priority high burden non-bacterial pathogens (namely: malaria and HIV), in order to represent a near complete burden of AMR across geography and time.
- Development of sustainable engagement plan for GBD-AMR collaborators and thereby create a sustainable AMR data repository post 2025.
- Tailored capacity building in LMICs
- Tailor and amplify the existing GRAM-1 multi-channel dissemination platform